References
1 Atkinson AJ
Jr., Colburn WA, De Gruttola VG, De Mets DL, Downing GJ, Hoth DF, Oates JA, Peck CC, Schooley RT, Spilker BA, Woodcock J, Zeger SL. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin Pharmacol Ther 2001 69:89-95
2 Folkman J. Tumor angiogenesis: therapeutic implications N Engl J Med 1971 285:1182-1186
3 Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy J Clin Oncol 2002 20:4368-4380
4 Miller KD. Recent translational research: antiangiogenic therapy for breast cancerwhere do we stand? Breast Cancer Res 2004 6:128-132
5 Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA,
et al. Differentiation and definition of vascular-targeted therapies Clin Cancer Res 2005 11:416-420
6 Banerjee S, Dowsett M, Ashworth A, Martin LA. Mechanisms of disease: angiogenesis and the management of breast cancer Nat Clin Pract Oncol 2007 4:536-550
7 Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG,
et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 2007 11:83-95
8 Miller KD. E2100: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer.
41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL;
2005.9 Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase iii clinical trials on anti-vegf therapy for cancer Nat Clin Pract Oncol 2006 3:24-40
10 Le Serve AW, Hellmann K. Metastases and the normalization of tumour blood vessels by ICRF159: a new type of drug action Br Med J 1972 1:597-601
11 Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 2005 307:58-62
12 Gasparini G. Clinical significance of determination of surrogate markers of angiogenesis in breast cancer Crit Rev Oncol Hematol 2001 37:97-114
13 Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesnt tell us J Natl Cancer Inst 2002 94:883-893
14 Pathak AP, Gimi B, Glunde K, Ackerstaf E, Artemov D,
et al. Molecular and functional imaging of cancer: advances in MRI and MRS Methods Enzymol 2004 386:3-60
15 Schenck JF. The role of magnetic susceptibility in magnetic resonance imaging: MRI magnetic compatibility of the first and second kinds Med Phys 1996 23:815-850
16 Rosen BR. Susceptibility contrast imaging of cerebral blood volume: human experience Magn Reson Med 1991 22:293-299
17 Villringer A, Rosen BR, Belliveau JW, Ackerman JL, Lauffer RB,
et al. Dynamic imaging with lanthanide chelates in normal brain: contrast due to magnetic susceptibility effects Magn Reson Med 1988 6:164-174
18 Zierler KL. Theoretical basis of indicator-dilution methods for measuring flow and volume Circ Res 1962 10:393-407
19 Fisel CR, Ackerman JL, Buxton RB, Garrido L, Belliveau JW,
et al. MR contrast due to microscopically heterogeneous magnetic susceptibility: numerical simulations and applications to cerebral physiology Magn Reson Med 1991 17:336-347
20 Kennan RP. Intravascular susceptibility contrast mechanisms in tissues Magn Reson Med 1994 31:9-21
21 Boxerman JL, Hamberg LM, Rosen BR, Weisskoff RM. MR contrast due to intravascular magnetic susceptibility perturbations Magn Reson Med 1995 34:555-566
22 Yablonskiy DA. Quantitation of intrinsic magnetic susceptibility-related effects in a tissue matrix: phantom study Magn Reson Med 1998 39:417-428
23 Kiselev VG. On the theoretical basis of perfusion measurements by dynamic susceptibility contrast MRI Magn Reson Med 2001 46:1113-1122
24 Corot C, Robert P, Idee JM, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging Adv Drug Deliv Rev 2006 58:1471-1504
25 Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging Eur Radiol 2001 11:2319-2331
26 Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH,
et al. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging Radiology 1990 175:489-493
27 Weisskoff RM, Zuo CS, Boxerman JL, Rosen BR. Microscopic susceptibility variation and transverse relaxation: theory and experiment Magn Reson Med 1994 31:601-610
28 Tropres I, Grimault S, Vaeth A, Grillon E, Julien C,
et al. Vessel size imaging Magn Reson Med 2001 45:397-408
29 Saini S, Frankel RB, Stark DD, Ferrucci JT. Magnetism: a primer and review Am J Roentgenol 1988 150:735-743
30 Cullity BD. Definitions and units Introduction to Magnetic Materials Addison-Wesley Reading, MA 1972 1-18
31 Josephson L, Lewis J, Jacobs P, Hahn PF, Stark DD. The effects of iron oxides on proton relaxivity Magn Reson Imaging 1988 6:647-653
32 Pouliquen D, Perroud H, Calza F, Jallet P, Le Jeune JJ. Investigation of the magnetic properties of iron oxide nanoparticles used as contrast agent for MRI Magn Reson Med 1992 24:75-84
33 Tanimoto A, Oshio K, Suematsu M, Pouliquen D, Stark DD. Relaxation effects of clustered particles J Magn Reson Imaging 2001 14:72-77
34 Virchow R: In:
Hirschwald A: ed. Die krankhaften geschwulste August Hirschwald Berlin 1863
35 Konerding M, van Ackern C, Fait E, Steinberg F, Streffer C. Morphological aspects of tumor angiogenesis and microcirculation Blood Perfusion and Microenvironment of Human Tumors: Implications for Clinical Radiooncology (Medical Radiology) Springer Verlag New York 2000 5-17
36 Jain RK. Determinants of tumor blood flow: a review Cancer Res 1988 48:2641-2658
37 Maeda M, Itoh S, Kimura H, Iwasaki T, Hayashi N,
et al. Tumor vascularity in the brain: evaluation with dynamic susceptibility-contrast MR imaging Radiology 1993 189:233-238
38 Pathak AP, Schmainda KM, Ward BD, Linderman JR, Rebro KJ,
et al. MR-derived cerebral blood volume maps: Issues regarding histological validation and assessment of tumor angiogenesis Magn Reson Med 2001 46:735-747
39 Aronen HJ, Gazit IE, Louis DN, Buchbinder BR, Pardo FS,
et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histological findings Radiology 1994 191:41-51
40 Donahue KM, Krouwer HG, Rand SD, Pathak AP, Marszalkowski CS,
et al. Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients Magn Reson Med 2000 43:845-853
41 Schmainda KM, Rand SD, Joseph AM, Lund R, Ward BD,
et al. Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis Am J Neuroradiol 2004 25:1524-1532
42 Pathak AP, Rand SD, Schmainda KM. The effect of brain tumor angiogenesis on the in vivo relationship between the gradient-echo relaxation rate change (deltar2*) and contrast agent (MION) dose J Magn Reson Imaging 2003 18:397-403
43 Barbier EL, Lamalle L, Decorps M. Methodology of brain perfusion imaging J Magn Reson Imaging 2001 13:496-520
44 Ostergaard L. Principles of cerebral perfusion imaging by bolus tracking J Magn Reson Imaging 2005 22:710-717
45 Thompson HKJ, Starmer CF, Whalen RE, McIntosh HD. Indicator transit time considered as a gamma-variate Circ Res 1964 14:502-515
46 Weisskoff RM. Pitfalls in MR measurement of tissue blood flow with intravascular tracers: which mean transit time? Magn Reson Med 1993 29:553-559
47 Quarles CC, Schmainda KM. Assessment of the morphological and functional effects of the anti-angiogenic agent su11657 on 9l gliosarcoma vasculature using dynamic susceptibility contrast MRI Magn Reson Med 2007 57:680-687
48 Le Duc G, Peoc`h M, Remy C, Charpy O, Muller RN,
et al. Use of T(2)-weighted susceptibility contrast MRI for mapping the blood volume in the glioma-bearing rat brain Magn Reson Med 1999 42:754-761
49 Dennie J, Mandeville JB, Boxerman JL, Packard SD, Rosen BR,
et al. NMR imaging of changes in vascular morphology due to tumor angiogenesis Magn Reson Med 1998 40:793-799
50 Shen T, Weissleder R, Papisov M, Bogdanov A Jr, Brady TJ. Monocrystalline iron oxide nanoparticles (MION): physiochemical properties Magn Reson Med 1993 29:599-604
51 Wu EX, Tang H, Jensen JH. Applications of ultrasmall superparamagnetic iron oxide contrast agents in the MR study of animal models NMR Biomed 2004 17:478-483
52 Bremer C, Mustafa M, Bogdanov A Jr, Ntziachristos V, Petrovsky A,
et al. Steady-state blood volume measurements in experimental tumors with different angiogenic burdens a study in mice Radiology 2003 226:214-220
53 Ogawa S. Oxygenation-sensitive contrast in MR image of rodent brain at high magnetic fields Magn Reson Med 1990 14:68-78
54 Robinson SP, Rijken PF, Howe FA, McSheehy PM, van der Sanden BP,
et al. Tumor vascular architecture and function evaluated by non-invasive susceptibility MRI methods and immunohistochemistry J Magn Reson Imaging 2003 17:445-454
55 Persigehl T, Bieker R, Matuszewski L, Wall A, Kessler T,
et al. Antiangiogenic tumor treatment: early noninvasive monitoring with USPIO-enhanced MR imaging in mice Radiology 2007 244:449-456
56 Robinson SP, Howe FA, Griffiths JR, Ryan AJ, Waterton JC. Susceptibility contrast magnetic resonance imaging determination of fractional tumor blood volume: a noninvasive imaging biomarker of response to the vascular disrupting agent zd6126 Int J Radiat Oncol Biol Phys 2007 69:872-879
57 Kostourou V, Robinson SP, Whitley GS, Griffiths JR. Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumor angiogenesis assessed by susceptibility magnetic resonance imaging Cancer Res 2003 63:4960-4966
58 Reichardt W, Hu-Lowe D, Torres D, Weissleder R, Bogdanov A Jr. Imaging of vegf receptor kinase inhibitor-induced antiangiogenic effects in drug-resistant human adenocarcinoma model Neoplasia 2005 7:847-853
59 Leenders WP, Kusters B, Verrijp K, Maass C, Wesseling P,
et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option Clin Cancer Res 2004 10:6222-6230
60 Ferretti S, Allegrini PR, O`Reilly T, Schnell C, Stumm M,
et al. Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure Clin Cancer Res 2005 11:7773-7784
61 Robinson SP, Ludwig C, Paulsson J, Ostman A. The effects of tumor-derived platelet-derived growth factor on vascular morphology and function in vivo revealed by susceptibility MRI Int J Cancer 2008 122:1548-1556
62 Pathak AP, Schmainda KM, Ward BD, Rebro KJ, Rand SD: Assessing tumor angiogenesis with dynamic susceptibility contrast fMRI: which morphologic correlates are relevant?
Ninth Annual Meeting of the International Society for Magnetic Resonance in Medicine. Glasgow;
2001.63 Yablonskiy DA, Haacke EM. Theory of NMR signal behavior in magnetically inhomogeneous tissues: the static dephasing regime Magn Reson Med 1994 32:749-763
64 Kiselev VG, Posse S. Analytical model of susceptibility-induced MR signal dephasing: effect of diffusion in a microvascular network Magn Reson Med 1999 41:499-509
65 Jensen JH, Chandra R. MR imaging of microvasculature Magn Reson Med 2000 44:224-230
66 Wu EX, Tang H, Jensen JH. High-resolution MR imaging of mouse brain microvasculature using the relaxation rate shift index q NMR Biomed 2004 17:507-512
67 Hahn PF, Stark DD, Weissleder R, Elizondo G, Saini S,
et al. Clinical application of superparamagnetic iron oxide to MR imaging of tissue perfusion in vascular liver tumors Radiology 1990 174:361-366
68 Ichikawa T, Arbab AS, Araki T, Touyama K, Haradome H,
et al. Perfusion MR imaging with a superparamagnetic iron oxide using T2-weighted and susceptibility-sensitive echoplanar sequences: evaluation of tumor vascularity in hepatocellular carcinoma Am J Roentgenol 1999 173:207-213
69 Neuwelt EA, Varallyay CG, Manninger S, Solymosi D, Haluska M,
et al. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study Neurosurgery 2007 60:601-611
70 Kiselev VG. Transverse relaxation effect of mri contrast agents: a crucial issue for quantitative measurements of cerebral perfusion J Magn Reson Imaging 2005 22:693-696
71 Marques JP, Bowtell RW: Simulations of the bold effect using a realistic model of the vasculature.
ISMRM, 12th Annual Meeting. Kyoto;
2004.72 Pathak AP, Ward BD, Schmainda KM. A novel technique for modeling susceptibility-based contrast mechanisms for arbitrary microvascular geometries: the finite perturber method Neuroimage 2008 40:1130-1143